32,921 Shares in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Purchased by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. acquired a new position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 32,921 shares of the medical device company’s stock, valued at approximately $808,000. Harbor Capital Advisors Inc. owned approximately 0.05% of Tandem Diabetes Care as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. grew its stake in Tandem Diabetes Care by 40.5% in the first quarter. JPMorgan Chase & Co. now owns 133,397 shares of the medical device company’s stock valued at $15,512,000 after purchasing an additional 38,460 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Tandem Diabetes Care by 2.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 6,246 shares of the medical device company’s stock worth $726,000 after acquiring an additional 164 shares during the period. Great West Life Assurance Co. Can raised its holdings in Tandem Diabetes Care by 7.5% in the 1st quarter. Great West Life Assurance Co. Can now owns 34,482 shares of the medical device company’s stock valued at $4,122,000 after acquiring an additional 2,402 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Tandem Diabetes Care by 68.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 185,408 shares of the medical device company’s stock valued at $21,561,000 after acquiring an additional 75,358 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its holdings in Tandem Diabetes Care by 3.4% in the 1st quarter. Canada Pension Plan Investment Board now owns 5,616 shares of the medical device company’s stock valued at $654,000 after acquiring an additional 184 shares in the last quarter.

Tandem Diabetes Care Stock Up 1.8 %

Shares of NASDAQ:TNDM opened at $22.14 on Tuesday. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.38 and a quick ratio of 3.53. The business’s 50-day moving average is $28.93 and its 200-day moving average is $32.01. Tandem Diabetes Care, Inc. has a 1 year low of $21.01 and a 1 year high of $58.82.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, August 3rd. The medical device company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.24. Tandem Diabetes Care had a negative return on equity of 20.29% and a negative net margin of 28.40%. The company had revenue of $195.92 million for the quarter, compared to the consensus estimate of $201.62 million. On average, research analysts anticipate that Tandem Diabetes Care, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TNDM has been the subject of several analyst reports. Robert W. Baird dropped their price objective on Tandem Diabetes Care from $33.00 to $32.00 and set a “neutral” rating for the company in a report on Monday, August 21st. Craig Hallum decreased their price target on Tandem Diabetes Care from $74.00 to $50.00 in a research note on Tuesday, June 13th. Wells Fargo & Company decreased their price target on Tandem Diabetes Care from $40.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Friday, August 4th. TD Cowen decreased their price target on Tandem Diabetes Care from $52.00 to $34.00 and set an “outperform” rating on the stock in a research note on Friday, August 4th. Finally, StockNews.com assumed coverage on Tandem Diabetes Care in a research note on Thursday, August 17th. They issued a “hold” rating on the stock. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $46.80.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.